Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
G. Ippolito, V. Galati, D. Serraino, E. Girardi.
The changing picture of the HIV/AIDS epidemic.
Ann N Y Acad Sci, 946 (2001), pp. 1-12
[2.]
J.P. Raynauld.
Cardiovascular mortality in rheumatoid arthritis: how harmful are corticosteroids?.
J Rheumatol, 24 (1997), pp. 415-416
[3.]
M. Petri, S. Perez-Gutthann, D. Spence, M.C. Hochberg.
Risk factors for coronary artery disease in patients with systemic lupus erythematosus.
Am J Med, 93 (1992), pp. 513-519
[4.]
M.P. Dube, D. Sprecher, W.K. Henry, J.A. Aberg, F.J. Torriani, H.N. Hodis, et al.
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
Clin Infect Dis, 31 (2000), pp. 1216-1224
[5.]
National Cholesterol Education Program. Second Report of the National Cholesterol Education Program on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
Circulation, 89 (1994), pp. 1329-1445
[6.]
L. Masana, E. Negredo, J. Pedro-Botet, B. Clotet.
Guía del manejo de las dislipemias en pacientes infectados por el VIH.
[7.]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
Jama, 285 (2001), pp. 2486-2497
[8.]
Ministerio de Sanidad, Consumo.
Control de la colesterolemia en España, 2000.
pp. 1-71
[9.]
The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.
Jama, 251 (1984), pp. 365-374
[10.]
S.P. Azen, W.J. Mack, L. Cashin-Hemphill, L. LaBree, A.M. Shircore, R.H. Selzer, et al.
Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Circulation, 93 (1996), pp. 34-41
[11.]
V. Manninen, L. Tenkanen, P. Koskinen, J.K. Huttunen, M. Manttari, O.P. Heinonen, et al.
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
Circulation, 85 (1992), pp. 37-45
[12.]
C.G. Ericsson, A. Hamsten, J. Nilsson, L. Grip, B. Svane, U. de Faire.
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
Lancet, 347 (1996), pp. 849-853
[13.]
Anónimo.
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.
Circulation, 102 (2000), pp. 21-27
[14.]
H.B. Rubins, S.L. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, et al.
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of HDL cholesterol.
N Engl J Med, 341 (1999), pp. 410-418
[15.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. Macfarlaine, et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med, 333 (1995), pp. 1301-1307
[16.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, G.C. Coles, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. CARE Study.
N Engl J Med, 335 (1996), pp. 1001-1009
[17.]
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N Engl J Med, 339 (1998), pp. 1349-1357
[18.]
J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, et al.
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. AFCAPS/ TexCAPS.
Jama, 279 (1998), pp. 1615-1622
[19.]
The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[20.]
Anónimo.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial.
Lancet, 360 (2002), pp. 7-22
[21.]
P.S. Phillips, R.H. Haas, S. Bannykh, S. Hathaway, N.L. Gray, B.J. Kimura, et al.
Statin-associated myopathy with normal creatine kinase levels.
Ann Intern Med, 137 (2002), pp. 581-585
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.